DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Indo Borax & Chemicals Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 2 hrs ago·10 Oct 2026, 6:15 am

Indo Borax & Chemicals

Indo Borax & Chemicals Limited has informed the stock exchanges that it has received a Certificate under SEBI (Depositories and Participants) Regulations, 2018. This document confirms that the company’s shares are fully dematerialized and that its depository participant is in compliance with the regulations.

This compliance is a routine administrative requirement for listed companies and serves as a confirmation that the company's shareholding structure is transparent and adheres to market norms. For investors, this news is a standard update that does not indicate any operational changes or financial distress.

Investors should monitor the company's future announcements for any material developments. This current update is primarily procedural and does not alter the investment outlook for the stock.